OMT-111 for Terminal Stage Solid Tumors

Breast Cancer Clinical Trial

Official title:

A Multi-site, Single Arm, Phase II Clinical Trial, to Evaluate the Efficacy of OMT-111 in Supporting the Treatment of Terminal Stage Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04520386
• Other study ID #: Metimedi-202
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 2020
• Est. completion date: October 2022

Study information

• Verified date: September 2020
• Source: MetiMedi Pharmaceuticals
• Contact: DongChul Kim
• Phone: 84-93-510-7310
• Email: dongchool.kim[@]bigleapresearch.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with terminal stage of metastatic non-small cell lung cancer, metastatic triple negative breast cancer, or advanced or metastatic pancreatic adenocarcinoma resisting to standard therapies.

Description:

This is a multi-site, single arm, Phase II study designed to explore the efficacy of OMT-111 in patients with terminal stage solid tumors resistant to standard therapies.

Subjects who voluntarily provide written consent to participate in this study undergo screening tests within 4 weeks prior to the first dose of investigational product. Those who meet the inclusion/exclusion criteria are enrolled in the study.

1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval (20 days of treatment and 8 days of treatment-free interval per cycle in total). This study is planned to enroll approximately 76 subjects including 42 subjects with lung cancer, 22 subjects with breast cancer, and 12 subjects with pancreatic cancer. Treatment will be provided for 12 cycles (48 weeks). During the study, tests and procedures to evaluate the efficacy and safety will be carried out according to the planned schedule.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 78
• Est. completion date: October 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Breast Cancer

1. Female at least 18 years old or older at the time of informed consent

2. Histologically or cytologically confirmed triple negative ductal adenocarcinoma of breast

3. Patients who have visceral metastatic lesions not amenable by resection or radiotherapy (e.g., multiple visceral lesions)

4. ECOG PS (Eastern Cooperative Oncology Group Performance Status): 0-2

5. Patients with a life expectancy = 12 weeks as judged by the investigator

6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

• Pancreatic Cancer

1. Male or female at least 18 years old or older at the time of informed consent

2. Histologically or cytologically confirmed adenocarcinoma of pancreas

3. Patients who have advanced or metastatic lesions not amenable by resection or radiotherapy

4. ECOG PS (Eastern Cooperative Oncology Group Performance Status) = 2

5. Patients with a life expectancy = 12 weeks as judged by the investigator

6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

• Lung Cancer

1. Male or female at least 18 years old or older at the time of informed consent

2. Histologically or cytologically confirmed carcinoma of the lung (small cell lung cancer not included)

3. Patients who have unresectable metastatic lesion

4. ECOG PS (Eastern Cooperative Oncology Group Performance status) = 2

5. Patients with a life expectancy = 12 weeks as judged by the investigator

6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Exclusion Criteria:

• Breast Cancer

1. History of malignancy other than metastatic triple negative breast cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)

2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days without steroids) are eligible)

3. Primary cancer-related complications potentially requiring urgent surgery as judged by the investigator

4. Grade = 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0

5. History of one or more of the following cardiovascular diseases

• Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)

• Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)

• Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator

• QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1)

6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1)

7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis

8. Previous treatment with the investigational product

9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product

10. Unable to come to the site hospital on a daily basis for investigational product administration

11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment.

• Pancreatic Cancer

1. History of malignancy other than advanced or metastatic pancreatic adenocarcinoma within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)

2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days without steroids) are eligible)

3. Primary cancer-related complication potentially requiring urgent surgery as judged by the investigator

4. Grade = 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0

5. History of one or more of the following cardiovascular diseases

• Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)

• Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)

• Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator

• QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1)

6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1)

7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis

8. Previous treatment with the investigational product

9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product

10. Unable to come to the site hospital on a daily basis for investigational product administration

11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment

• Lung Cancer

1. History of malignancy other than metastatic non-small cell lung cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)

2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days) are eligible)

3. Primary cancer-related complication potentially requiring urgent surgery as judged by the investigator

4. Grade = 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0

5. History of one or more of the following cardiovascular diseases

• Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)

• Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)

• Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator

• QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1)

6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1)

7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis

8. Previous treatment with the investigational product

9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product

10. Unable to come to the site hospital on a daily basis for investigational product administration

11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment

Related Conditions & MeSH terms

• Breast Cancer
• Lung Cancer
• Pancreatic Cancer

Intervention

Drug:
• OMT-111
Pre-filled Syringe

Locations

Country	Name	City	State
Vietnam	K Hospital	Hanoi
Vietnam	Cho Ray Hospital	Hochiminh city

Sponsors (1)

Lead Sponsor	Collaborator
MetiMedi Pharmaceuticals

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Control Rate (DCR)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
Secondary	Objective Response Rate (ORR)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
Secondary	Duration of Response (DoR)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
Secondary	Progression-Free Survival (PFS)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
Secondary	18F-FDG- PET/CT (SUVmean and SUVmax)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.